<DOC>
	<DOCNO>NCT02562183</DOCNO>
	<brief_summary>In order reevaluate safety efficacy human urinary kallikrein treat acute cerebral infarction , multi-center , open label , single group study design . Expect enroll 60 site 2186 subject . Subjects receive treatment 21 day kallikrein 90 day follow-up .</brief_summary>
	<brief_title>The Study Reevaluate Safety Efficacy Human Urinary Kallikrein</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<criteria>1 . Acute anterior circulation cerebral infarction diagnose ≤ 48h ; 2 . First time diagnosed history acute anterior circulation cerebral infarction without serious sequela ( mRS=02 ) ; 3 . Age 18 80 year old ; 4 . National Institute Health stroke scale ( NIHSS ) 6 25 ; 5 . Have provide sign write informed consent patient patient 's legal representative . 1 . Brain CT show cerebral hemorrhage disease : cerebral hemorrhage , subarachnoid hemorrhage , etc . 2 . Transient ischemic attack ( TIA ) ; 3 . Serious disturbance consciousness : Glasgow Coma ScaleGCS（GCS）≤8 ; 4 . Combined angiotensinconverting enzyme inhibitor ( ACEI ) less 5 halftime ( accord instruction ) , need treat ACEI ; 5 . Cases treat thrombolysis / stent surgery expect treated thrombolysis / interventional therapy / stent surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>